MedTrace Logo

Mexiletine for the Treatment of Muscle Cramps in ALS

NCT01811355 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2017-08-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if mexiletine is effective for the treatment of muscle cramps in Amyotrophic Lateral Sclerosis (ALS).

Conditions

  • Muscle Cramps in Amyotrophic Lateral Sclerosis

Interventions

DRUG

Mexiletine

Sodium channel blocker

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • University of California, Davis

    collaborator OTHER

  • ALS Association

    collaborator OTHER

  • Bjorn Oskarsson, MD

    lead OTHER

Principal Investigators

  • Bjorn Oskarsson, MD · UC Davis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2016-03-31
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01811355 on ClinicalTrials.gov